BIM
NKTR icon

BlackRock Investment Management’s Nektar Therapeutics NKTR Stock Holding History

BlackRock Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$9M Buy
48,907
+12,580
+35% +$2.56M 0.01% 1183
2016
Q3 		$9.36M Sell
36,327
-1,904
-5% -$490K 0.01% 1047
2016
Q2 		$8.16M Sell
38,231
-5,321
-12% -$1.19M 0.01% 1079
2016
Q1 		$8.98M Buy
43,552
+1,094
+3% +$210K 0.01% 990
2015
Q4 		$10.7M Buy
42,458
+562
+1% +$116K 0.01% 899
2015
Q3 		$6.89M Buy
41,896
+3,342
+9% +$591K 0.01% 1155
2015
Q2 		$7.24M Buy
38,554
+13,626
+55% +$2.34M 0.01% 1218
2015
Q1 		$4.11M Buy
24,928
+115
+0.5% +$23.6K 0.01% 1518
2014
Q4 		$5.77M Buy
24,813
+72
+0.3% +$15.4K 0.01% 1264
2014
Q3 		$4.48M Buy
24,741
+155
+0.6% +$29.7K 0.01% 1409
2014
Q2 		$4.73M Sell
24,586
-85
-0.3% -$15K 0.01% 1426
2014
Q1 		$4.49M Buy
24,671
+1,971
+9% +$390K 0.01% 1448
2013
Q4 		$3.87M Sell
22,700
-542
-2% -$87.4K 0.01% 1536
2013
Q3 		$3.64M Buy
23,242
+896
+4% +$166K 0.01% 1504
2013
Q2 		$3.87M Buy
+22,346
New +$3.43M 0.01% 1394

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Investment Management's NKTR Position: Q4 2016 in Review

BlackRock Investment Management increased its Nektar Therapeutics (NKTR) stake by 35% in Q4 2016, buying an estimated $2.56M and bringing the position to 48,907 shares worth $9M. The position accounts for 0.01% of the portfolio, ranked #1183.

BlackRock Investment Management first reported a position in NKTR in Q2 2013 and has held it in 15 quarters since. The position peaked at $10.7M in Q4 2015. 199 funds tracked by Wall St. Rank hold NKTR as of Q4 2016.

  • BlackRock Investment Management held 48,907 shares of Nektar Therapeutics worth $9M as of Q4 2016.
  • BlackRock Investment Management bought 12,580 Nektar Therapeutics shares in Q4 2016, an estimated $2.56M.
  • Nektar Therapeutics made up 0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1183 holding.
  • BlackRock Investment Management first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Nektar Therapeutics position peaked at $10.7M in Q4 2015.
  • 199 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.